4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
3.800
+0.360 (10.47%)
At close: May 19, 2025, 4:00 PM
3.820
+0.020 (0.53%)
After-hours: May 19, 2025, 7:17 PM EDT
4D Molecular Therapeutics Stock Forecast
FDMT's stock price has decreased by -85% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for 4D Molecular Therapeutics stock ranges from a low of $6.00 to a high of $44. The average analyst price target of $32.33 forecasts a 750.79% increase in the stock price over the next year.
Price Target: $32.33 (+750.79%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for 4D Molecular Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 5 | 5 | 4 | 4 | 4 | 4 |
Buy | 4 | 4 | 4 | 4 | 4 | 4 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 1 | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 11 | 11 | 10 | 10 | 10 | 10 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Chardan Capital | Chardan Capital | Strong Buy Maintains $28 → $25 | Strong Buy | Maintains | $28 → $25 | +557.89% | May 9, 2025 |
Goldman Sachs | Goldman Sachs | Strong Buy Maintains $51 → $44 | Strong Buy | Maintains | $51 → $44 | +1,057.89% | May 9, 2025 |
Barclays | Barclays | Buy Maintains $45 → $38 | Buy | Maintains | $45 → $38 | +900.00% | May 9, 2025 |
B of A Securities | B of A Securities | Strong Buy Maintains $42 → $40 | Strong Buy | Maintains | $42 → $40 | +952.63% | Mar 10, 2025 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $30 → $28 | Strong Buy | Maintains | $30 → $28 | +636.84% | Mar 4, 2025 |
Financial Forecast
Revenue This Year
4.88M
from 37.00K
Increased by 13,097.30%
Revenue Next Year
4.26M
from 4.88M
Decreased by -12.82%
EPS This Year
-3.64
from -2.98
EPS Next Year
-3.93
from -3.64
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 21.0M | 21.0M | 21.0M | ||
Avg | 4.9M | 4.3M | 4.7M | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 56,656.8% | 330.1% | 393.3% | ||
Avg | 13,097.3% | -12.8% | 10.3% | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -3.14 | -2.98 | -1.63 | ||
Avg | -3.64 | -3.93 | -3.95 | ||
Low | -4.61 | -5.40 | -6.28 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.